SCHEMBL3453746

SCHEMBL3453746

CCOC(=O)N1C2CCC1CC(N1CCN(c3ncc(-c4ccccc4)cc3C#N)CC1)C2

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 2/20 0.48
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CHRM1 P11229 8/20 0.44
GRM5 P41594 1/20 0.42
ACACB O00763 1/20 0.42
CHRM5 P08912 2/20 0.40
CHRM4 P08173 1/20 0.40
CHRM2 P08172 1/20 0.40
NR1H2 P55055 2/20 0.40
NR1H3 Q13133 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604310 0.86 ALDH1A1 (0.47) P2RY12KDM4EALDH1A1HTTL3MBTL1
SCHEMBL3453802 0.83 KDM4E (0.51) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL13698551 0.80 CHRM1 (0.50) CHRM1GRM5CHRM5CHRM4CHRM2
SCHEMBL3453583 0.77 GRM5 (0.44) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL5197445 0.77 MAPT (0.42) KDM4EALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3453501 0.75 ALDH1A1 (0.44) P2RY12KDM4EALDH1A1CHRM1
SCHEMBL3454291 0.75 PANK3 (0.49) HPGDCHRM1
SCHEMBL3453688 0.75 ALDH1A1 (0.65) KDM4EALDH1A1HTTL3MBTL1MEN1
SCHEMBL3453576 0.74 HRH3 (0.51) CHRM1GRM5CHRM4
SCHEMBL13698552 0.74 CHRM1 (0.44) CHRM1CHRM5CHRM4CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820817-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-26 US claimed
US-20100105693-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-29 US claimed
EP-1753429-A1 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-02-21 EP claimed
US-20060019962-A1 substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain VERTEX PHARMACEUTICALS INCORPORATED 2006-01-26 US claimed
WO-2005117883-A1 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-12-15 WO claimed
EP-1753429-A1 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-02-21 EP disclosed
WO-2005117883-A1 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105693-A1 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 P2RY12 137/4885KDM4E 2719/4885ALDH1A1 2741/4885
US-20060019962-A1 substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain ACHE, CHRM5, CHRM3 P2RY12 105/4885KDM4E 2477/4885ALDH1A1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.